Pharmacokinetic monitoring of HIV-1 protease inhibitors in the antiretroviral therapy

Acta Poloniae Pharmaceutica - Drug Research

Volumn 65, Issue 1, 2008, Pages 93-100

  Pawiński, Tomasz ^a   Pulik, Piotr ^b   Gralak, Beata ^a   Horban, Andrzej ^b  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b SP ZOZ Wojewodzki Szpital Zakazny Centrum Diagnostyki i Terapii AIDS Warszawa   (Poland)

Author keywords

Antiretroviral therapy; HPLC; Protease inhibitors; Therapeutic drug monitoring

Indexed keywords

DIAZEPAM; INDINAVIR; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; RITONAVIR; SAQUINAVIR;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MONITORING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION;

ADULT; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG COMBINATIONS; DRUG MONITORING; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; INDINAVIR; MIDDLE AGED; NELFINAVIR; PYRIMIDINONES; SAQUINAVIR;

EID: 42549163224     PISSN: 00016837     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Back D., Gibbons S., Khoo S.: Ther. Drug Monit. 28, 468 (2006).
2. Boffito M., Acosta E., Burger D., Fletcher C.V., et al.: Antiviral Therapy 10, 375 (2005).
3. Back D.J., Khoo S.H., Gibbons S.E., Merry C.: Br. J. Clin. Pharmacol. 52, 89S (2001).
4. Kappelhoff B.S., Crommentuyn K.M.L., de Maat M.M.R., Mulder J.W., Huitema A.D.R., Beijnen J.H.: Clin. Pharmacokinet. 43, 845 (2004).
5. King J.R., Wynn H., Brundage R., Acosta E.P.: Clin. Pharmacokinet. 43, 291 (2004).
6. Boffito M., Acosta E., Burger D., Fletcher C.V., et al.: Antiviral Therapy 10, 469 (2005).
7. Yamada H., Kotaki H., Nakamura T., Iwamoto A.: J. Chromatogr. B 755, 85 (2001).
8. Donnerer J., Kronawetter M., Kapper A., Haas I., Kessler H.H.: Pharmacology 69, 197 (2003).
9. Keil K., Frerichs V.A., DiFrancesco R., Morse G.: Ther. Drug Monit. 25, 340 (2003).
10. Poirier J-M., Radembino N., Robidou P., Jaillon P.: Ther. Drug Monit. 22, 465 (2000)
11. Marzolini C., Telenti A., Buclin T., Biollaz J., Decosterd L.A.: J. Chromatogr. B 740, 43 (2000).
12. Walson P.D.,Cox S., Utkin I., Gerber N., Crim L., Brady M., Koranyi K.: Ther. Drug Monit. 25, 588 (2003).
13. Droste J.A.H., Verweij van Wissen C.P.W.G. M., Burger D.M.: Ther. Drug Monit. 25, 393 (2003).
14. Bouley M., Briere C., Padoin C., Petitjean O,. Tod M.: Ther. Drug Monit. 23, 56 (2001).
15. Back D. J., Khoo S.H., Gibbons S.E., Barry M.G., Merry C.: Ther. Drug Monit. 22, 122 (2000).
16. Burton M.E., Shaw L.M., Schentag J.J., Evans W.E.: Applied Pharmacokinetics & Pharmacodynamics. Principles of Therapeutic Drug Monitoring. p. 354, Lippincott Williams & Wilkins, Philadelphia 2006.
17. Shah V.P., Midha K.K, Dighe S., et al.: Eur. J. Drug Metab. Pharmacokin. 16: 249 (1991).
18. Pawiński T., Pulik P., Gralak B., Horban A.: Ther. Drug Monit. 29, 513 (2007).
19. Dasgupta A., Okhuysen P.C.: Ther. Drug Monit. 23, 591 (2001).
20. Van Heeswijk R.P.G.: Ther. Drug Monit. 24, 323 (2002).